Bristol-Myers Squibb (NYSE:BMY) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 11.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 225,265 shares of the biopharmaceutical company’s stock after selling 29,605 shares during the period. AEGON ASSET MANAGEMENT UK Plc’s holdings in Bristol-Myers Squibb were worth $12,748,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Geneos Wealth Management Inc. raised its position in shares of Bristol-Myers Squibb by 3.9% in the 4th quarter. Geneos Wealth Management Inc. now owns 95,955 shares of the biopharmaceutical company’s stock worth $5,427,000 after buying an additional 3,560 shares during the period. Accel Wealth Management increased its stake in Bristol-Myers Squibb by 6.2% during the fourth quarter. Accel Wealth Management now owns 4,674 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 271 shares during the last quarter. Carr Financial Group Corp lifted its stake in shares of Bristol-Myers Squibb by 8.4% in the 4th quarter. Carr Financial Group Corp now owns 4,643 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 361 shares in the last quarter. CX Institutional grew its holdings in shares of Bristol-Myers Squibb by 2.5% during the 4th quarter. CX Institutional now owns 135,290 shares of the biopharmaceutical company’s stock worth $7,652,000 after purchasing an additional 3,255 shares during the period. Finally, Sound Income Strategies LLC increased its position in Bristol-Myers Squibb by 117.1% during the 4th quarter. Sound Income Strategies LLC now owns 6,014 shares of the biopharmaceutical company’s stock worth $340,000 after purchasing an additional 3,244 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Trading Up 0.9 %

NYSE:BMY opened at $59.68 on Friday. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The company has a market cap of $121.05 billion, a PE ratio of -16.63, a P/E/G ratio of 2.02 and a beta of 0.45. The business’s 50 day moving average is $57.47 and its two-hundred day moving average is $52.54.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.00 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a dividend of $0.62 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.16%. Bristol-Myers Squibb’s dividend payout ratio is -69.08%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Citigroup lifted their price target on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, November 12th. Morgan Stanley increased their price target on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. TD Cowen boosted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, Barclays lifted their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $56.27.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.